IP Library Granted Patent US 11,707,483
Granted Patent B2
US 11,707,483 · App. 16/579,662 · Granted Jul 25, 2023

Micellic assemblies

Inventors: Patrick S. Stayton (Seattle, WA); Allan S. Hoffman (Seattle, WA); Anthony Convertine (Seattle, WA); Craig L. Duvall (Nashville, TN); Danielle Benoit (Rochester, NY); Robert Overell (Shoreline, WA); Paul H. Johnson (Snohomish, WA); Anna S. Gall (Woodinville, WA); Mary G. Prieve (Lake Forest Park, WA); Amber E. E. Paschal (Redmond, WA); Charbel Diab (Seattle, WA); Priyadarsi De (Mohanpur, IN)
Assignees: UNIVERSITY OF WASHINGTON; GENEVANT SCIENCES GMBH
A61K31/713A61K9/1075A61K47/549A61K47/58A61K47/60A61K47/6907A61K48/0041C08F290/062C08F293/005C12N15/111C12N15/87C12N2320/32Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,707,483
App. No.
16/579,662
Granted
Jul 25, 2023
Kind
B2
Abstract

Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.

Claims (49)

1. A micelle-like assembly, wherein the micelle-like assembly comprises a plurality of block copolymers of Formula I:

wherein

A 0 , A 1 , A 2 , A 3 and A 4 are independently selected from the group consisting of —C—, —C—C—, —C(O)(C) a C(O)O—, —O(C) a C(O)—, and —O(C) b O—; wherein,

a is 1-4;

b is 2-4;

Y 4 is selected from the group consisting of hydrogen, -(1C-10C)alkyl,-(3C-6C)cycloalkyl, —O—(1C-10C)alkyl, —C(O)O(1C-10C)alkyl, -(4C-10C)heteroaryl, and -(6C-10C)aryl, any of which is optionally substituted with one or more fluorine groups;

Y 0 , Y 1 , and Y 2 are independently selected from the group consisting of a covalent bond, -(1C-10C)alkyl-, —C(O)O(2C-10C) alkyl-, —OC(O)(1C-10C) alkyl-, —O(2C-10C)alkyl-, —S(2C-10C)alkyl-, —C(O)NR 6 (2C-10C) alkyl-, -(4C-10C)heteroaryl-, and -(6C-10C)aryl-;

Y 3 is selected from the group consisting of a covalent bond, -(1C-10C)alkyl-, -(4C-10C)heteroaryl-, and -(6C-10C)aryl-;

wherein tetravalent carbon atoms of A 0 -A 4 that are not fully substituted with R 1 -R 5 and Y 0 -Y 4 are completed with an appropriate number of hydrogen atoms;

R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from the group consisting of hydrogen, —CN, alkyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, any of which may be optionally substituted with one or more fluorine atoms;

Q 0 is a residue selected from the group consisting of residues which are hydrophilic at physiologic pH; conjugatable or functionalizable residues; and hydrogen;

Q 1 is a residue which is hydrophilic at physiological pH;

Q 2 is a residue which is positively charged at physiological pH;

Q 3 is a residue which is negatively charged at physiological pH, but undergoes protonation at lower pH;

m is a mole fraction of about 0 to less than 1.0;

n is a mole fraction of greater than 0 to about 1.0; wherein m+n=1;

p is a mole fraction of 0.1 to 0.9;

q is a mole fraction of 0.1 to 0.9;

r is present up to a mole fraction of 0.8; wherein p+q+r=1;

v is from about 1 to about 25 kDa; and

w is from about 1 to about 50 kDa.

2. The micelle-like assembly of claim 1 , wherein Q 1 is a polyethylene glycol group.

3. The micelle-like assembly of claim 1 , wherein the micelle-like assembly comprises at least one therapeutic agent.

4. The micelle-like assembly of claim 3 , wherein the therapeutic agent is associated with the copolymer.

5. The micelle-like assembly of claim 4 , wherein the therapeutic agent is ionically associated with the copolymer.

6. The micelle-like assembly of claim 3 , wherein the therapeutic agent is a polynucleotide, an oligonucleotide, a gene expression modulator, a knockdown agent, an siRNA, an RNAi agent, a dicer substrate, an miRNA, an shRNA, an antisense oligonucleotide, or an aptamer.

7. The micelle-like assembly of claim 3 , wherein the therapeutic agent is an siRNA.

8. The micelle-like assembly of claim 1 , wherein v is from about 5 to about 25 kDa.

9. The micelle-like assembly of claim 1 , wherein w is from about 5 to about 50 kDa.

10. The micelle-like assembly of claim 1 , wherein the ratio of w to v is from 5:1 to 1:1.

11. The micelle-like assembly of claim 1 , wherein Q 0 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, thiol, azide, alkyne, succinimide ester, tetrafluorophenyl ester, pentafluorophenyl ester, p-nitrophenyl ester, pyridyl disulfide, and hydrogen;

Q 1 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, and thiol;

Q 2 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, and pyridyl; and

Q 3 is a residue selected from the group consisting of carboxyl, sulfonamide, boronate, phosphonate, and phosphate.

12. The micelle-like assembly of claim 1 , wherein

R 3 -A 2 -Y 2 -Q 2 is a residue of dimethylaminoethylmethacrylate (DMAEMA),

R 4 -A 3 -Y 3 -Q 3 is a residue of propyl acrylic acid (PAA), and

R 5 -A 4 -Y 4 is a residue of butyl methacrylate (BMA).

13. The micelle-like assembly of claim 1 , wherein the diblock copolymer, having the chemical Formula I is a diblock copolymer of the Formula IV2:

wherein

p is a mole fraction of 0.1 to 0.9;

q is a mole fraction of 0.1 to 0.9;

r is present up to a mole fraction of 0.8, wherein p+q+r=1;

v is from 1 to 25 kDa;

w is from 1 to 50 kDa; and

Z − is a physiological acceptable counterion.

14. The micelle-like assembly of claim 13 , wherein Z − is selected from the group consisting of hydroxide, chloride, phosphate, sulfate, sulfonate, acetate, propionate, butyrate, valerate, caproate, caprylate, caprate, laurate, myristate, palmate, stearate, palmitolate, oleate, linolate, arachidate, gadoleate, vaccinate, lactate, glycolate, salicylate, desamionphenylalanine, desaminoserine, desaminothreonine, E-hydroxycaproate, 3-hydroxybutylrate, 4-hydroxybutyrate and 3-hydroxyvalerate.

15. The micelle-like assembly of claim 13 , wherein Z − is hydroxide.

16. A composition comprising the micelle-like assembly of claim 1 .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2021
From: PHASERX, INC.
To: ROIVANT HEPATOLOGY GMBH
Reel/Frame 057683/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2021
From: ROIVANT HEPATOLOGY GMBH
To: GENEVANT SCIENCES GMBH
Reel/Frame 057689/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2021
From: STAYTON, PATRICK S; HOFFMAN, ALLAN S; CONVERTINE, ANTHONY J; DUVALL, CRAIG L; BENOIT, DANIELLE
To: UNIVERSITY OF WASHINGTON
Reel/Frame 057221/0098 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2021
From: JOHNSON, PAUL H; OVERELL, ROBERT W; GALL, ANNA S; PRIEVE, MARY G; PASCHAL, AMBER E; DIAB, CHARBEL; DE, PRIYADARSI
To: PHASERX, INC.
Reel/Frame 057221/0138 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 3, 2020
From: GENEVANT SCIENCES LTD.
To: ROIVANT SCIENCES LTD.
Reel/Frame 052312/0930 →
Continuity (10)
Continuation 15499683 · Apr 27, 2017
Continuation 15059026 · Mar 2, 2016
Continuation 12992525
Provisional Application 61171369 · Apr 21, 2009
Provisional Application 61140774 · Dec 24, 2008
Provisional Application 61112048 · Nov 6, 2008
Provisional Application 61091294 · Aug 22, 2008
Provisional Application 61052908 · May 13, 2008
Provisional Application 61052914 · May 13, 2008
Related Publication 20200147121A1 · May 14, 2020